You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

TREATMENT OF PERSISTENT SEROUS RETINAL DETACHMENT IN VOGTKOYANAGIHARADA SYNDROME WITH INTRAVITREAL BEVACIZUMAB DURING THE SYSTEMIC STEROID TREATMENT

Reibaldi, Michele MD, PhD*; Russo, Andrea MD, PhD*; Avitabile, Teresio MD*; Uva, Maurizio G. MD*; Franco, Livio MD*; Longo, Antonio MD, PhD*; Toro, Mario D. MD*; Cennamo, Gilda MD, PhD; Mariotti, Cesare MD; Neri, Piergiorgio MD; Noci, Nicola D. MD§; Russo, Vincenzo MD, PhD§

Retina:
doi: 10.1097/IAE.0b013e3182a0e446
Original Study
Abstract

Purpose: To report the use of bevacizumab in patients with Vogt–Koyanagi–Harada disease and persistent serous retinal detachment during the systemic steroid treatment.

Methods: Four patients with bilateral Vogt–Koyanagi–Harada disease with the resolution of ocular inflammation presenting a serous retinal detachment involving the fovea that persisted for at least 1 month, despite systemic corticosteroid treatment, received an intravitreal injection of bevacizumab during the steroid tapering stage. Best-corrected visual acuity, central retinal thickness, and macular sensitivity were evaluated.

Results: Of 8 eyes, 7 (87%) had complete resolution of subretinal fluid within 1 month following the treatment. After the treatment, the mean best-corrected visual acuity and macular sensitivity improved significantly (P < 0.001, analysis of variance). Compared with baseline, at all measurements, central retinal thickness decreased significantly (P < 0.01, Tukey–Kramer test). At 6 months, a significant correlation was found between best-corrected visual acuity and macular sensitivity in the central 8° (linear regression, r = −0.73; P = 0.03), whereas no correlation was found between central retinal thickness and both best-corrected visual acuity and macular sensitivity.

Conclusion: Intravitreal injection of bevacizumab during the corticosteroid therapy may be a treatment option for patients with decreased visual function because of persistent serous retinal detachment associated with Vogt–Koyanagi–Harada syndrome.

In Brief

Intravitreal bevacizumab was injected into eight eyes of four patients with Vogt&amp;#x2013;Koyanagi&amp;#x2013;Harada disease and persistent serous retinal detachment during tapering of systemic steroid treatment. Patients responded with prompt resolution of serous retinal detachment and improvement in visual acuity and retinal sensitivity after a single injection of bevacizumab.

Author Information

*Department of Ophthalmology, University of Catania, Catania, Italy;

Department of Ophthalmology, University of Napoli, Naples, Italy;

Department of Ophthalmology, University of Ancona, Ancona, Italy; and

§Department of Ophthalmology, University of Foggia, Foggia, Italy.

Reprint requests: Andrea Russo, MD, PhD, Department of Ophthalmology, University of Catania, Italy, Via S. Sofia 78, 95124, Catania, Italy; e-mail: andrearusso2000@hotmail.com

None of the authors have any financial/conflicting interests to disclose.

© 2014 by Ophthalmic Communications Society, Inc.